Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects .
There was no evidence of any serious harm caused by statin prescription .
Evidence available to date showed that primary prevention with statins is likely to be cost-effective and may improve patient quality of life .
Recent findings from the Cholesterol Treatment Trialists study using individual patient data meta- analysis indicate that these benefits are similar in people at lower ( < 1 % per year ) risk of a major cardiovascular event .
AUTHORS ' CONCLUSIONS Reductions in all-cause mortality , major vascular events and revascularisations were found with no excess of adverse events among people without evidence of CVD treated with statins
BACKGROUND Reducing high blood cholesterol , a risk factor for cardiovascular disease ( CVD ) events in people with and without a past history of CVD is an important goal of pharmacotherapy .
Statins are the first-choice agents .
Previous review s of the effects of statins have highlighted their benefits in people with CVD .
The case for primary prevention was uncertain when the last version of this review was published ( 2011 ) and in light of new data an up date of this review is required .
OBJECTIVES To assess the effects , both harms and benefits , of statins in people with no history of CVD .
Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein
Objectives : Non-HDL-cholesterol ( non-HDL-C ) and apolipoprotein ( apo ) B are proposed as treatment targets . The extent to which statin therapy affects relationships of LDL-C and non-HDL-C with apoB was examined in type 2 diabetes . Methods : Analyses were performed in 217 hypertriglyceridaemic type 2 diabetic patients ( Diabetes Atorvastatin Lipid Intervention ( DALI ) cohort ) . 61 patients r and omized to placebo , 70 to 10 mg atorvastatin daily and 65 – 80 mg atorvastin daily completed follow-up . Results : Baseline fasting LDL-C of 2.42 mmol/l and non-HDL-C of 3.69 mmol/l corresponded to the apoB guideline target of 0.90 g/l . During atorvastatin ( 10 and 80 mg daily ) , the LDL-C target was achieved most frequently , and lower LDL-C ( 2.38 and 2.29 mmol/l ) and non-HDL-C ( 3.24 and 3.19 mmol/l ) concentrations corresponded to this apoB goal . Decreases in LDL-C during  atorvastatin  treatment were negatively related ( p < 0.001 ) , but decreases in non-HDL-C were positively related to changes in triglycerides ( p < 0.001 ) , independently from decreases in apoB ( p < 0.001 for all ) . Decreases in LDL-C and non-HDL-C were positively associated with decreases in cholesteryl ester transfer protein mass ( p < 0.001 ) . Conclusions : During atorvastatin  lower LDL-C and non-HDL-C levels correspond to the apoB guideline target , which would favour its use as treatment target
Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects .
There was no evidence of any serious harm caused by statin prescription .
Evidence available to date showed that primary prevention with statins is likely to be cost-effective and may improve patient quality of life .
Recent findings from the Cholesterol Treatment Trialists study using individual patient data meta- analysis indicate that these benefits are similar in people at lower ( < 1 % per year ) risk of a major cardiovascular event .
AUTHORS ' CONCLUSIONS Reductions in all-cause mortality , major vascular events and revascularisations were found with no excess of adverse events among people without evidence of CVD treated with statins
BACKGROUND Reducing high blood cholesterol , a risk factor for cardiovascular disease ( CVD ) events in people with and without a past history of CVD is an important goal of pharmacotherapy .
Statins are the first-choice agents .
Previous review s of the effects of statins have highlighted their benefits in people with CVD .
The case for primary prevention was uncertain when the last version of this review was published ( 2011 ) and in light of new data an up date of this review is required .
OBJECTIVES To assess the effects , both harms and benefits , of statins in people with no history of CVD .